Prime Medicine, Inc.PRMEEarnings & Financial Report
Nasdaq
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
PRME Q3 2025 Key Financial Metrics
Revenue
$1.2M
Gross Profit
N/A
Operating Profit
$-54.0M
Net Profit
$-50.6M
Gross Margin
N/A
Operating Margin
-4406.0%
Net Margin
-4129.1%
YoY Growth
486.1%
EPS
$-0.32
Financial Flow
Prime Medicine, Inc. Q3 2025 Financial Summary
Prime Medicine, Inc. reported revenue of $1.2M for Q3 2025, with a net profit of $-50.6M (-4129.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.2M |
|---|---|
| Net Profit | $-50.6M |
| Gross Margin | N/A |
| Operating Margin | -4406.0% |
| Report Period | Q3 2025 |
Prime Medicine, Inc. Annual Revenue by Year
Prime Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $3.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $3.0M |
| 2023 | $0 |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $591000 | $0 | $209000 | $2.2M | $1.5M | $1.1M | $1.2M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 146.0% | N/A | 486.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $193.9M | $311.4M | $259.7M | $332.8M | $297.5M | $328.2M | $279.0M | $385.0M |
| Liabilities | $60.8M | $67.6M | $63.1M | $143.3M | $144.4M | $221.2M | $218.1M | $223.2M |
| Equity | $133.1M | $243.8M | $196.6M | $189.5M | $153.1M | $106.9M | $60.9M | $161.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-43.9M | $-67.7M | $-45.5M | $-25.9M | $16.2M | $-48.9M | $-41.4M | $-35.0M |